iTeos Therapeutics Reports Promising Results for Belrestotug

Promising Interim Data from iTeos Therapeutics' Study

iTeos Therapeutics, Inc. (NASDAQ: ITOS) has recently shared encouraging interim results from their pivotal GALAXIES Lung-201 study. This clinical trial is focused on evaluating the effectiveness of the combination therapy of belrestotug and dostarlimab for treating patients with advanced non-small cell lung cancer (NSCLC) who are PD-L1 high. The results highlighted a significant objective response rate (ORR) of 63.3% to 76.7%, demonstrating substantial efficacy in this patient population.

Insightful Results from the GALAXIES Lung-201 Study

As per the latest data cut-off, the study comprised 124 patients evaluated for both safety and efficacy. Between the treatment arm of belrestotug combined with dostarlimab and the dostarlimab monotherapy, a remarkable difference of over 30% in confirmed ORR was reported. This reinforces the potential of using the TIGIT:PD-1 doublet therapy as a formidable option compared to conventional therapies.

Positive Feedback from Experts

Dr. Michel Detheux, the CEO of iTeos, expressed optimism regarding these findings. He stated that achieving a consistent confirmed ORR of around 60% across three distinct dosages of the combo demonstrates significant potential for better outcomes in patients who have limited treatment options. Additionally, the clinical improvements in tumor response rates are particularly encouraging.

Expert Commentary on the Treatment Landscape

Dr. Brian Henick from Columbia University emphasized that the ongoing search for patient-centric treatment options is crucial for tackling this serious condition. The interim data from the GALAXIES Lung-201 study showcases notable progress, indicating that the belrestotug and dostarlimab combination may be shaping into a compelling alternative for NSCLC treatments.

Trial Design and Efficacy Measures

The GALAXIES Lung-201 study is designed to compare novel immunotherapy combinations against standard treatments in patients with advanced stages of lung cancer. The study arms feature several treatment combinations, including pembrolizumab monotherapy, dostarlimab monotherapy, and a potent combination of belrestotug and dostarlimab.

The primary endpoint of this study focuses on the ORR as assessed by investigators, with secondary objectives surrounding safety, progression-free survival, and overall survival metrics. Several patients have also shown considerable ctDNA reduction across various dosages, further characterizing the efficacy of belrestotug and dostarlimab together.

Safety Profile Consistent with Prior Findings

Throughout the study, the safety profile of belrestotug in tandem with dostarlimab has displayed consistency with previously understood outcomes of checkpoint inhibitors. Though some immune-related adverse events occurred with the combination therapy, these were reported as manageable.

Upcoming Conference to Discuss Findings

iTeos Therapeutics is set to host a conference call to delve deeper into the findings and implications of the GALAXIES Lung-201 study. Attendees will have the opportunity to hear directly from the research team about the exciting developments and ongoing studies in the pipeline.

About iTeos Therapeutics

iTeos Therapeutics is paving the way in the development of next-generation immuno-oncology therapies for serious health conditions. With a strong foundational understanding of tumor immunology, the company is committed to bringing innovative solutions to patients in need. Their clinical pipeline includes multiple projects addressing vital immunosuppressive pathways, with a focus on promising therapeutic candidates.

Frequently Asked Questions

What were the key findings of the GALAXIES Lung-201 study?

The study reported an objective response rate of 63.3% to 76.7% with belrestotug combined with dostarlimab, showing significant efficacy compared to dostarlimab monotherapy.

Who is the CEO of iTeos Therapeutics?

Dr. Michel Detheux serves as the president and CEO of iTeos Therapeutics, overseeing the company's innovative therapies and trials.

What does the term PD-L1 high indicate?

PD-L1 high indicates that the tumor expresses a high level of the programmed death-ligand 1, which can be targeted effectively by certain therapies, like belrestotug and dostarlimab.

How is the safety of the combination therapy characterized?

The safety profile of the belrestotug and dostarlimab combination has been consistent with known profiles of checkpoint inhibitors, with adverse events considered manageable.

When is the follow-up data expected?

iTeos Therapeutics anticipates additional follow-up data from this trial in the coming years, particularly for insights expected in 2025.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.